Manufacturer
Baxter Oncology GmbH
Contents
Mesna
Indication
Prevention of urotoxic effects of oxazaphosphorines.
Instruction
If Uromitexan is given by IV at 1st instance, the oral dose at -2 hrs should be replaced by IV at 0 hr.
Drug interaction
Mesna is incompatible in vitro with cisplatin and nitrogen mustard.